scholarly journals Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part III: The Comet Assay as an Alternative to In Vitro Clastogenicity Tests for Early Drug Candidate Selection

2007 ◽  
Vol 97 (1) ◽  
pp. 21-26 ◽  
Author(s):  
I. Witte ◽  
U. Plappert ◽  
H. de Wall ◽  
A. Hartmann
Keyword(s):  
Comet Assay ◽  
Safety Evaluation ◽  
Toxicity Assessment ◽  
Candidate Selection ◽  
Drug Candidate ◽  
Genetic Toxicity ◽  
Human Safety ◽  
Early Drug

scholarly journals Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation

2006 ◽  
Vol 96 (1) ◽  
pp. 1-1 ◽  
Author(s):  
J. I. Goodman ◽  
B. Gollapudi ◽  
L. D. Lehman-McKeeman
Keyword(s):  
Safety Evaluation ◽  
Toxicity Assessment ◽  
Genetic Toxicity ◽  
Human Safety

scholarly journals Lopinavir-ritonavir is not an effective inhibitor of the main protease activity of SARS-CoV-2 in vitro

2020 ◽  
Author(s):  
Minsu Jang ◽  
Yea-In Park ◽  
Rackhyun Park ◽  
Yeo-Eun Cha ◽  
Sim Namkoong ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Combination Therapy ◽  
Candidate Selection ◽  
Hiv Protease ◽  
Drug Candidate ◽  
Effective Inhibitor ◽  
Clinical Tests ◽  
Main Protease ◽  
Selection For

ABSTRACTCOVID-19 has caused over 900,000 deaths worldwide as of September 2020, and effective medicines are urgently needed. Lopinavir was identified as an inhibitor of the HIV protease, and a lopinavir-ritonavir combination therapy was reported to be beneficial for the treatment of SARS and MERS. However, recent clinical tests could not prove that lopinavir-ritonavir therapy was an effective treatment for COVID-19. In this report, we examined the effect of lopinavir and ritonavir to the activity of the purified main protease (Mpro) protein of SARS- CoV-2, the causative virus of COVID-19. Unexpectedly, lopinavir and ritonavir did not inhibit Mpro activity. These results will aid the drug candidate selection for ongoing and future COVID-19 clinical trials.

Strategy of Utilizing In Vitro and In Vivo ADME Tools for Lead Optimization and Drug Candidate Selection

2005 ◽  
Vol 5 (11) ◽  
pp. 1033-1038 ◽  
Author(s):  
Suresh Balani ◽  
Gerald Miwa ◽  
Liang-Shang Gan ◽  
Jing-Tao Wu ◽  
Frank Lee
Keyword(s):  
Lead Optimization ◽  
Candidate Selection ◽  
Drug Candidate

scholarly journals Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDerm™)

2015 ◽  
Vol 13 (1) ◽  
Author(s):  
John W. Wills ◽  
Nicole Hondow ◽  
Adam D. Thomas ◽  
Katherine E. Chapman ◽  
David Fish ◽  
...  
Keyword(s):  
Toxicity Assessment ◽  
Engineered Nanoparticles ◽  
Skin Model ◽  
Genetic Toxicity ◽  
In Vitro Skin Model
Sign in / Sign up

Export Citation Format

Share Document